Search Results for: SRC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
ESR2 estrogen receptor 2
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • Diethylstilbestrol
  • Conjugated estrogens
  • Progesterone
  • Raloxifene
  • Estrone
  • Tamoxifen
  • Estradiol
  • Trilostane
  • Estramustine
  • Oxybenzone
  • Genistein
  • Prasterone
  • Benzophenone
  • Phthalic Acid
  • Pyrazole
  • Para-Mercury-Benzenesulfonic Acid
  • Naringenin
  • ICI-164384
  • 5-Alpha-Androstane-3-Beta,17beta-Diol
  • 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol
  • Quercetin
  • Afimoxifene
  • Estriol
  • Estrone sulfate
  • MF101
  • CHF 4227
  • TAS-108
  • Lasofoxifene
  • Arzoxifene
  • Bazedoxifene
  • Prinaberel
  • ERB-196
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL
  • 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL
  • 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL
  • (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol
  • 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL
  • 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME
  • 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE
  • 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE
  • 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 17alpha-Estriol
  • (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one
  • Erteberel
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • Eugenol
  • Octocrylene
  • Enzacamene
  • Equol
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
  • Estriol tripropionate
  • Fluoroestradiol F-18
ETS1 ETS proto-oncogene 1, transcription factor
  • Oncogene Induced Senescence
ETS2 ETS proto-oncogene 2, transcription factor
  • Oncogene Induced Senescence
EVL Enah/Vasp-like
  • Generation of second messenger molecules
  • Signaling by ROBO receptors
  • Signaling by ROBO receptors
  • RHO GTPases Activate Formins
FARP2 FERM, ARH/RhoGEF and pleckstrin domain protein 2
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
FBP2 fructose-bisphosphatase 2
  • Gluconeogenesis
FBXO5 F-box protein 5
  • SCF-beta-TrCP mediated degradation of Emi1
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Mitotic Metaphase/Anaphase Transition
  • G1/S-Specific Transcription
FGR FGR proto-oncogene, Src family tyrosine kinase
  • FCGR activation
  • Platelet sensitization by LDL
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Dasatinib
  • Fostamatinib
  • Zanubrutinib
FRS2 fibroblast growth factor receptor substrate 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
FYB1 FYN binding protein 1
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • Signal regulatory protein family interactions
FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
GAB2 GRB2 associated binding protein 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
GAB3 GRB2 associated binding protein 3
GALNT12 polypeptide N-acetylgalactosaminyltransferase 12
  • Defective GALNT12 causes colorectal cancer 1 (CRCS1)
  • O-linked glycosylation of mucins
GIT1 GIT ArfGAP 1
  • Ephrin signaling
  • Ephrin signaling
  • Activation of RAC1 downstream of NMDARs
GRB10 growth factor receptor bound protein 10
  • Signaling by SCF-KIT
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • RET signaling
  • FLT3 Signaling
  • Response of EIF2AK1 (HRI) to heme deficiency
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • MECP2 regulates neuronal receptors and channels
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic acid
  • Glycine
  • Tramadol
  • Enflurane
  • Atomoxetine
  • Pentobarbital
  • Methadone
  • Secobarbital
  • Meperidine
  • Acamprosate
  • Donepezil
  • Guaifenesin
  • Felbamate
  • Memantine
  • Halothane
  • Phenobarbital
  • Aripiprazole
  • Tenocyclidine
  • Prasterone
  • Milnacipran
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Esketamine
  • Fluciclovine (18F)
GRIN2B glutamate ionotropic receptor NMDA type subunit 2B
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • RAF/MAP kinase cascade
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • MECP2 regulates neuronal receptors and channels
  • Activated NTRK2 signals through FYN
  • Assembly and cell surface presentation of NMDA receptors
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Glutamic acid
  • Tramadol
  • Enflurane
  • Atomoxetine
  • Pentobarbital
  • Methadone
  • Secobarbital
  • Meperidine
  • Haloperidol
  • Acamprosate
  • Donepezil
  • Guaifenesin
  • Felbamate
  • Memantine
  • Phenobarbital
  • Aripiprazole
  • Tenocyclidine
  • Prasterone
  • Taurine
  • Milnacipran
  • EVT-101
  • Lumateperone
  • Acetylcysteine
  • Ketobemidone
  • Gavestinel
  • Ifenprodil
  • Magnesium acetate tetrahydrate
  • Magnesium carbonate
  • Esketamine
  • Esketamine
  • Fluciclovine (18F)

Page 9 out of 16 pages